Zilebesiran is an investigational RNA interference therapeutic developed to reduce blood pressure by targeting hepatic angiotensinogen. By silencing the upstream precursor of the renin-angiotensin cascade, zilebesiran produces sustained suppression of angiotensinogen and prolonged antihypertensive activity. Its dosing paradigm—designed to provide infrequent administrations for select ambulatory populations—makes it attractive for long-term blood pressure control.
Early-phase studies established that zilebesiran causes durable angiotensinogen suppression and measurable reductions in blood pressure. Phase 2 trials extended these findings to clinically stable outpatients, confirming antihypertensive efficacy in that setting. A larger trial, KARDIA-3, evaluated zilebesiran in patients with uncontrolled hypertension and established or high cardiovascular risk who were receiving multiple antihypertensive agents; however, KARDIA-3 did not meet its prespecified multiplicity-adjusted threshold for statistical significance at month 3. The body of trial data to date has demonstrated pharmacodynamic effects and clinical blood pressure lowering, while also highlighting modulators of response and considerations for safety in specific contexts.
Trial data and physiologic considerations indicate that the antihypertensive response to zilebesiran is not uniform. Dietary sodium intake modulates blood pressure response, and background pharmacologic blockade of the renin-angiotensin-aldosterone system (RAAS) also alters outcomes. These interactions underline that patient characteristics and concomitant therapies influence both efficacy and practical management when zilebesiran is used alongside standard antihypertensive regimens.
A central unresolved clinical question addressed by the authors is how to manage acute illness when upstream RAAS suppression from angiotensinogen silencing cannot be rapidly attenuated. Situations of concern include sepsis, perioperative stress, acute heart failure, marked volume depletion, and hyperkalemia—clinical contexts in which clinicians commonly rely on temporary adjustment or withholding of oral RAAS inhibitors to manage hemodynamics, renal function, or electrolyte disturbances. The prolonged pharmacodynamic effect of zilebesiran raises the possibility of reduced short-term therapeutic flexibility during these episodes.
Importantly, the concern articulated is about potential limitations in acute-care flexibility rather than demonstration of harm from existing trials. The reviewed evidence did not report that prolonged angiotensinogen silencing has produced definitive adverse outcomes in these acute scenarios; instead, it emphasized uncertainty about management pathways if rapid reversal were needed.
The authors note that early reversal strategies for angiotensinogen silencing are conceptually important but that currently available approaches seem more applicable to planned de-escalation than to emergency rescue. In other words, options that might mitigate the effects of prolonged RAAS suppression could be workable when de-escalation is scheduled or anticipated, but their utility during unplanned acute deterioration is limited according to the current literature and trial experience summarized in this review.
Clinicians considering zilebesiran for long-term blood pressure management will need to weigh its sustained efficacy and dosing convenience against potential constraints in acute-care settings. The question of how to handle patients who receive zilebesiran and then develop sepsis, require urgent surgery, or present with acute heart failure or severe volume depletion remains open. Care pathways that rely on short-term modification of oral RAAS inhibitors may not be directly transferable to a setting where hepatic angiotensinogen suppression persists despite withholding oral agents.
As phase 3 development progresses, the authors identify several priorities:
These research questions are framed as necessary steps to ensure that therapeutic flexibility is preserved or appropriately managed as zilebesiran moves through later-stage clinical development.
The authors declare no potential conflicts of interest relevant to the content of the article. Ethics approval, consent to participate, and consent for publication were noted as not applicable in the article metadata.